Vaccination strategies for the last stages of global polio eradication

Indian Pediatrics

Volumn 42, Issue 2, 2005, Pages 163-169

  Bompart, François ^a  

^a SANOFI PASTEUR   (France)

Author keywords

Disease eradication; Poliomyelitis; Vaccination; Vaccine

Indexed keywords

INACTIVATED VIRUS VACCINE; ORAL POLIOMYELITIS VACCINE;

BIOLOGICAL WARFARE; ERADICATION THERAPY; HUMAN; IMMUNE DEFICIENCY; IMMUNOGENICITY; MUCOSAL IMMUNITY; POLIOMYELITIS; POLIOMYELITIS VIRUS; REVIEW; VACCINATION; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION;

BIOTERRORISM; DECISION MAKING; DEVELOPING COUNTRIES; HUMANS; IMMUNITY, MUCOSAL; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; VACCINATION; WORLD HEALTH;

EID: 14744278403     PISSN: 00196061     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (29)

1. Global Polio Eradication Initiative Strategic Plan 2004-2008. Weekly Epidemiol Record WHO 2004;6:55-57.
2. Kew OM, Wright PF, Agol VI. Delpeyroux F, Shimizu H, Nathanson N, Pallansch MA. Circulating vaccine-derived viruses: Current state of knowledge. Bull WHO 2004;82:16-23
3. Yang CF, et al. Circulation of endemic type 2 vaccine-derived polioviruses in Egypt from 1983 to 1193. J Virol 2004;77:8366-8377.
4. Progress towards the global eradication of poliomyelitis, 2001. Weekly Epidemiol Record WHO 2002;77:98-108.
5. Poliomyelitis - Madagascar, 2002. Weekly Epidemiol Record WHO 2002;77:20025.
6. Halsey NA, et al. Search for polio virus carriers among people with primary immune deficiency diseases in the United States, Mexico, Brazil, and the United Kingdom. Bull WHO 2004;82:3-8.
7. Poliovirus Type 2 (MEF-1) found in northern India. Polio Lab Network Quarterly Update, 2003; IX (3), 1.
8. Update on actions taken following the isolation of MEF-1 reference poliovirus associated with acute flaccid paralysis cases in India in late 2002 and early 2003. Weekly Epidemiol Record WHO 2003;78:284.
9. John TJ. Polio eradication in India: What is the future? Indian Pediatr 2003;40:455-462.
10. Kant L. Wild polioviruses: can we afford to leave them in the cold ? Indian J Med Res. 2004;119:iii-iv.
11. Minor, PD. Polio vaccines and the cessation of vaccination. Expert Rev Vaccines 2003;2:99-104.
12. Sutter RW, Caceres VM, Mas Lago P. The role of routine polio immunization in the post-certification era. Bull WHO, 2004;82:31-39.
13. Sutter RW, Caceres VM, Mas Lago P. The role of routine polio immunization in the postcertification era. Bull WHO, 2004;82:31-39.
14. Sangrujee N, Duintjer Tebbens RJ, Caceres V, Thompson K. Policy decision options during the first 5 years following certification of polio eradication. Medscape General Medicine 5(4), 2003. Available at: http://www.medscape. com/viewarticle/464841. Accessed September 7, 2004.
15. Plotkin S, Murdin A, Vidor E. Inactivated poliovirus vaccine. In Plotkin SA, Orenstein WA, editors. Vaccines, 3rd edition 1999:364-408.
16. WHO Collaborative Study Group. Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman and Thailand. J Infect Dis 1997;175(Suppl 1): S215-S227.
17. Nirmal S, Cherian T, Samuel BU, Rajasingh J, Raghupathy P, John TJ. Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine. Vaccine 1998;16:928-931.
18. Gylca R, Gylca V, Benes O, et al. A new DTaP-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTwP-IPV/Hib vaccine co-administered with HBV, given at 6, 10 and 14 weeks, following HBV at birth. Vaccine 2000;19:825-833.
19. Barrios J. IPV versus OPV: Results of the Cuban Clinical Trial. In: Program and Abstracts of the 11th International Congress on Infectious Diseases, Cancun, Mexico March 4-7, 2004. Abstract No. 53.003.
20. Fine PE, Carneiro AM. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol. 1999; 150,10:1001-1021.
21. Ghendon YUZ, Sanakoyeva II. Comparison of the resistance of the intestinal tract to poliomyelitis virus (Sabin's strains) in persons after naturally and experimentally acquired immunity. Acta Virologica (Praha) 1961;5: 265-273.
22. Onorato IM, Modlin JF, McBean AM, Thoms ML, Losonski GA, Bernier RH: Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis 1991;163:1-6.
23. Mascareñas A, Salinas J, Tasset-Tisseau A, Ortiz E. Polio intensive immunization week in Mexico: an economic burden assessment. In Program and Abstracts of the World Congress of Pediatric Infectious Diseases - WSPID. Santiago de Chile, Chile, Nov 2002 Abstract N°384.
24. John J. The Golden Jubilee of vaccination against poliomyelitis. Indian J Med Res 2004; 119:1-17.
25. Minor PD. Polio eradication, cessation of vaccination and re-emergence of disease. Nature Rev Microb 2004;2:473-482.
26. Nathanson N, Fine P. Poliomyelitis eradication, a dangerous endgame. Science 2002;296: 269-270.
27. Khuri-Bulos N. Polio eradication, rethinking the end-game. Lancet Inf. Dis. 2004;4:262-263.
28. Roberts L. The exit strategy. Science 2004; 303:1969-1970.
29. Heymann D.L. Polio eradication: finishing the job and protecting the investment. Bull WHO, 2004;82:1.